Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 4/2002

01-04-2002 | Review Article

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease

Authors: Dr Dirk Deleu, Margaret G. Northway, Yolande Hanssens

Published in: Clinical Pharmacokinetics | Issue 4/2002

Login to get access

Abstract

Current research in Parkinson’s disease (PD) focuses on symptomatic therapy and neuroprotective interventions. Drugs that have been used for symptomatic therapy are levodopa, usually combined with a peripheral decarboxylase inhibitor, synthetic dopamine receptor agonists, centrally-acting antimuscarinic drugs, amantadine, monoamine oxidase-B (MAO-B) inhibitors and catechol-O-methyltransferase (COMT) inhibitors. Drugs for which there is at least some evidence for neuroprotective effect are certain dopamine agonists, amantadine and MAO-B inhibitors (selegiline).
Levodopa remains the most effective drug for the treatment of PD. Several factors contribute to the complex clinical pharmacokinetics of levodopa: erratic absorption, short half-life, peripheral O-methylation and facilitated transport across the blood-brain barrier. In patients with response fluctuations to levodopa, the concentration-effect curve becomes steeper and shifts to the right compared with patients with stable response. Pharmacokinetic-pharmacodynamic modelling can affect decisions regarding therapeutic strategies.
The dopamine agonists include ergot derivatives (bromocriptine, pergolide, lisuride and cabergoline), non-ergoline derivatives (pramipexole, ropinirole and piribedil) and apomorphine. Most dopamine agonists have their specific pharmacological profile. They are used in monotherapy and as an adjunct to levodopa in early and advanced PD.
Few pharmacokinetic and pharmacodynamic data are available regarding centrally acting antimuscarinic drugs. They are characterised by rapid absorption after oral intake, large volume of distribution and low clearance relative to hepatic blood flow, with extensive metabolism.
The mechanism of action of amantadine remains elusive. It is well absorbed and widely distributed. Since elimination is primarily by renal clearance, accumulation of the drug can occur in patients with renal dysfunction and dosage reduction must be envisaged.
The COMT inhibitors entacapone and tolcapone dose-dependently inhibit the formation of the major metabolite of levodopa, 3-O-methyldopa, and improve the bioavailability and reduce the clearance of levodopa without significantly affecting its absorption. They are useful adjuncts to levodopa in patients with end-of-dose fluctuations.
The MAO-B inhibitor selegiline may have a dual effect: reducing the catabolism of dopamine and limiting the formation of neurotoxic free radicals. The pharmacokinetics of selegiline are highly variable; it has low bioavailability and large volume of distribution. The oral clearance is many-fold higher than the hepatic blood flow and the drug is extensively metabolised into several metabolites, some of them being active.
Despite the introduction of several new drugs to the antiparkinsonian armamentarium, no single best treatment exists for an individual patient with PD. Particularly in the advanced stage of the disease, treatment should be individually tailored.
Footnotes
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literature
1.
Weill E. De l’apomorphine dans certains troubles nerveux. Lyon Med 1884; 48: 411–9
2.
Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen der extrapyramidalen Systems. Klin Wochenschrift 1960; 38: 1236–9CrossRef
3.
Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–9PubMedCrossRef
4.
Bartholini G, Burkard WF, Pletscher A, et al. Increase in cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967; 215: 852–3PubMedCrossRef
5.
Deleu D, Hanssens Y. Current and emerging strategies in the management of Parkinson’s disease: a critical reappraisal. Saudi Med J 1997; 18: 115–26
6.
Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50 Suppl. 3:S1–57PubMedCrossRef
7.
Rabey JM, Vered Y, Shabtai H, et al. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 1992; 55: 725–7PubMedCrossRef
8.
Cedarbaum JM, Williamson R, Kutt H. Simultaneous determination of levodopa, its metabolites and carbidopa in clinical samples. J Chromatogr 1987; 415: 393–9PubMedCrossRef
9.
Deleu D, Sarre S, Ebinger G, et al. Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis. J Pharm Biomed Anal 1993; 11: 577–85PubMedCrossRef
10.
Michotte Y, Deleu D, Ebinger G. The use of capillary gas chromatography/mass spectrometry for the determination of acidic dopamine metabolites in human brain. Biomed Mass Spect 1985; 12: 704–6CrossRef
11.
Rondelli I, Acerbi D, Mariotti F, et al. Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994; 653: 17–23PubMedCrossRef
12.
Rahman MK, Nagatsu T, Kato T. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-DOPA and L-5-hydroxytryptophan as substrates. Biochem Pharmacol 1981; 30: 645–9PubMedCrossRef
13.
Lovenberg W, Victor SJ. Regulation of tryptophan and tyrosine hydroxylase. Life Sci 1974; 14: 2337–53PubMedCrossRef
14.
Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966; 18: 95–113PubMed
15.
Nissinen E, Tuominen R, Perhoniemi V, et al. Catechol-O-methytransferase and aromatic L-amino acid decarboxylase activities in human gastrointestinal tissues. Life Sci 1991; 49: 721–5CrossRef
16.
Abell CW. Monoamine oxidase A and B from human liver and brain. Methods Enzymol 1987; 142: 638–50PubMedCrossRef
17.
Benedetti MS, Dostert P. Commentary: monoamine oxidase, brain aging and degenerative disease. Biochem Pharmacol 1989; 38: 55–61
18.
Saura J, Kettler R, Da Prada M, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 1992; 12: 1977–99PubMed
19.
Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs 2000; 59: 1233–50PubMedCrossRef
20.
Cedarbaum JM, Kutt H, McDowell FH. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988; 21: 533–6CrossRef
21.
Alexander GM, Schwartzman RJ, Grothusen JR, et al. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naïve and MPTP parkinsonian monkeys. Neurology 1994; 44: 1491–9PubMedCrossRef
22.
Sandler M, Johnson RD, Ruthven CR, et al. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature 1974; 247: 364–6PubMedCrossRef
23.
Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationship between plasma and cerebrospinal fluid pharmacokinetics and clinical effect in Parkinson’s disease. Ann Neurol 1991; 29: 556–9PubMedCrossRef
24.
Goodall MC, Alton H. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects. Biochem Pharmacol 1972; 21: 2401–8PubMedCrossRef
25.
Da Prada M, Kettler R, Zurcher G, et al. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 1987; 27 Suppl. 1: 9–20PubMedCrossRef
26.
Kaakkola S, Mannisto PT, Nissinen E, et al. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 1985; 72: 385–91PubMedCrossRef
27.
Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987; 13: 141–78PubMedCrossRef
28.
Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadme hydrochloride. Clin Pharmacokinet 1988; 14: 35–51PubMedCrossRef
29.
Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadme hydrochloride in subjects with normal and impaired renal function. Ann Int Med 1981; 94: 454–8PubMed
30.
Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985; 18: 537–43PubMedCrossRef
31.
Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973; 242: 463–5PubMedCrossRef
32.
Robertson DRC, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990; 29: 47–53PubMedCrossRef
33.
Contin M, Riva R, Martinelli P, et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson’s disease. Eur J Clin Pharmacol 1991; 41: 463–6PubMedCrossRef
34.
Evans MA, Triggs EJ, Broe GA, et al. Systemic activity of orally administered L-dopa in the elderly Parkinson patient. Eur J Clin Pharmacol 1980; 17: 215–21PubMedCrossRef
35.
Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin Neuropharmacol 1987; 10: 527–37PubMedCrossRef
36.
Pfeiffer RF. Antiparkinsonian agents: drug interactions of clinical significance. Drug Safety 1996; 14: 343–54PubMedCrossRef
37.
Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson’s disease. Clin Neuropharmacol 1992; 15: 375–80PubMedCrossRef
38.
Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on L-dopa levels and clinical response in Parkinson’s disease. Mov Disord 1995; 10: 66–70PubMedCrossRef
39.
Reuter I, Harder S, Engelhardt M, et al. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2000; 15: 862–8PubMedCrossRef
40.
Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 1987; 37: 940–4PubMedCrossRef
41.
Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol 1987; 21: 370–6PubMedCrossRef
42.
Chase TN, Mouradian MM, Fabbrini G, et al. Pathogenetic studies of motor fluctuations in Parkinson’s disease. J Neural Transm Suppl 1988; 27: 3–10PubMed
43.
Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 1987; 44: 1006–9PubMedCrossRef
44.
Frankel JP, Kempster PA, Bovingdon M, et al. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 1989; 52: 1063–7PubMedCrossRef
45.
Nutt JG, Woodward WR, Carter JH, et al. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989; 52: 481–7PubMedCrossRef
46.
Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992; 49: 149–51PubMedCrossRef
47.
Hammerstad JP, Woodward WR, Gliessman P, et al. L-dopa Pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. Ann Neurol 1990; 27: 495–9PubMedCrossRef
48.
Cedarbaum JM, Olanow TI. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson’s disease. Neurology 1991; 41: 1567–70PubMedCrossRef
49.
Tyce GM, Ahlskog JE, Carmichael SW, et al. Catecholamines in CSF, plasma and, tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson’s disease. J Lab Clin Med 1989; 114: 185–92PubMed
50.
Tohgi H, Abe T, Kikuchi T, et al. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson’s disease. Neurosci Lett 1991; 132: 19–22PubMedCrossRef
51.
Tohgi H, Abe T, Takahashi S, et al. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson’s disease, and their changes after L-dopa administration. Neurosci Lett 1993; 159: 135–8PubMedCrossRef
52.
Deleu D, Sarre S, Ebinger G, et al. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism of blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. J Pharmacol Exp Ther 1995; 273: 1323–31PubMed
53.
Nutt JG, Holford NHG. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561–73PubMedCrossRef
54.
Frankel JP, Pirtosek Z, Kempster PA, et al. Diurnal differences in response to oral levodopa. J Neurol Neurosurg Psychiatry 1990; 53: 948–50PubMedCrossRef
55.
Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson’s disease. Neurology 1994; 44: 1287–92PubMedCrossRef
56.
Durso R, Isaac K, Perry L, et al. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry 1993; 56: 65–8PubMedCrossRef
57.
Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson’s disease. Clin Pharmacokinet 1995; 29: 243–56PubMedCrossRef
58.
Contin M, Riva R, Martinelli P, et al. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study. Clin Neuropharmacol 1997; 20: 409–18PubMedCrossRef
59.
Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996; 51: 59–67PubMedCrossRef
60.
Contin M, Riva R, Martinelli P, et al. A levodopa kinetic-dynamic study of the rate of progression in Parkinson’s disease. Neurology 1998; 51: 1075–80PubMedCrossRef
61.
Gancher ST, Nutt JG, Woodward W. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 1988; 38: 712–6PubMedCrossRef
62.
Zappia M, Colao R, Montesanti R, et al. Long-duration response to levodopa influences the pharmacodynamics of short duration response in Parkinson’s disease. Ann Neurol 1997; 42: 245–8PubMedCrossRef
63.
Zappia M, Bosco D, Piastino M, et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 1999; 53: 557–60PubMedCrossRef
64.
Barbato L, Stocchi F, Monge A, et al. The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol 1997; 20: 394–401PubMedCrossRef
65.
Paalzow GHM, Paalzow LK. L-dopa: how it may exacerbate parkinsonian symptoms. Trends Pharmacol Sci 1986; 9: 15–9CrossRef
66.
Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson’s disease. Ann Neurol 1989; 25: 523–6PubMedCrossRef
67.
Grahnén A, Eckernäs SA, Collin C, et al. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur Neurol 1992; 32: 343–8PubMedCrossRef
68.
Poewe WH, Lees AJ, Stern GM. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson’s disease and motor fluctuations. Eur Neurol 1987; 27 Suppl. 1: 93–7PubMed
69.
Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 1989; 12: 147–66PubMedCrossRef
70.
Deleu D, Jacques M, Michotte Y, et al. Controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology 1989; 39 Suppl. 2: 88–92PubMed
71.
Lewitt PA. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology 1992; 42 Suppl. 1: 29–32PubMedCrossRef
72.
Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93: 14–20PubMedCrossRef
73.
Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidiopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999; 53: 1012–9PubMedCrossRef
74.
Gasser UE, Crevoisier C, Ouwerkerk M, et al. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-relase formulation of levodopa and benserazide in healthy subjects. Eur J Pharm Biopharm 1998; 46: 223–8PubMedCrossRef
75.
Nutt JG, Carter JH, Woodward W, et al. Does tolerance develop to levodopa? Comparison of 2- and 21 -H levodopa infusions. MovDisord 1993; 8: 139–43CrossRef
76.
Juncos JL, Mouradian MM, Fabbrini G, et al. Levodopa infusion therapy. In: Koller WC, Paulson G, editors. Therapy of Parkinson’s disease. New York: Marcel-Dekker, 1990: 185–201
77.
Deleu D, Ebinger G, Michotte Y Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson’s disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991; 41: 453–8PubMedCrossRef
78.
Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebocontrolled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology 1993; 43: 1698–703PubMedCrossRef
79.
Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243–54PubMedCrossRef
80.
Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease. Drug Saf 1998; 19(1): 11–22PubMedCrossRef
81.
Melamed E, Offen D, Shirvan A, et al. Levodopa toxicity and apoptosis. Ann Neurol 1998; 44 Suppl. 1: S149–54PubMed
82.
83.
Cedarbaum JM, Gandy SE, McDowell FH. ‘Early’ initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson’s disease. Neurology 1991; 41: 622–9PubMedCrossRef
84.
Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol 1986; 19: 365–72PubMedCrossRef
85.
Stocchi F, Ruggieri S, Carta A, et al. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson’s disease. Mov Disord 1992; 7: 249–56PubMedCrossRef
86.
Steiger MJ, Stocchi F, Carta A, et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon ‘off’ periods in Parkinson’s disease. Clin Neuropharmacol 1991; 14: 241–4PubMedCrossRef
87.
Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson’s disease. Ann Neurol 1996; 39: 400–4PubMedCrossRef
88.
Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24: 125–32PubMedCrossRef
89.
Robertson GS, Robertson HA. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res 1986; 384: 387–90PubMedCrossRef
90.
Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of L-dopa-induced dyskinesias. MovDisord 1999; 14 Suppl. 1: 4–8
91.
Lange KW. Clinical pharmacology of dopamine agonists in Parkinson’s disease. Drugs Aging 1998; 13: 381–9PubMedCrossRef
92.
Lange KW, Rausch WD, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm Suppl. 1994; 43: 183–201PubMed
93.
Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838: 51–9PubMedCrossRef
94.
Zou L, Jankovic J, Rowe DB, et al. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999; 64: 1275–85PubMedCrossRef
95.
Grünblatt E, Mandel S, Berkuzki T, et al. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14: 612–8PubMedCrossRef
96.
Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232–8PubMedCrossRef
97.
Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991; 6: 212–6PubMedCrossRef
98.
Friis ML, Gron U, Larsen NE, et al. Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson’s disease. Eur J Clin Pharmacol 1979; 15: 275–80PubMedCrossRef
99.
Andreotti AC, Pianezzola E, Persiani S, et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995; 80: 841–5PubMedCrossRef
100.
Burns RS, Gopinathan G, Humpel M, et al. Disposition of oral lisuride in Parkinson’s disease. Clin Pharmacol Ther 1984; 35: 548–56PubMedCrossRef
101.
Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 1990; 39: 491–506PubMedCrossRef
102.
Jenner P. Parkinson’s disease: pathological mechanisms and actions of piribedil. J Neurol 1992; 239 Suppl. 1: S2–8PubMed
103.
Bennett Jr JP, Piercey MF. Pramipexole: a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 1999; 163: 25–31PubMedCrossRef
104.
Bowsher RR, Apathy JM, Compton JA, et al. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma. Clin Chem 1992; 38: 1975–80PubMed
105.
Haring N, Salarna Z, Jaeger H. Triple stage quadrupole mass spectrometric determination of bromocriptine in human plasma with negative ion chemical ionization. Arzneimittelfors 1988; 38: 1529–32
106.
Phelan DG, Greig NH, Rapoport SI, et al. High-performance liquid Chromatographic assay of bromocriptine in rat plasma and brain. J Chromatogr 1990; 533: 264–70PubMedCrossRef
107.
Wolthers BG, Verhagen Kamerbeek WD, van Beusekom CM, et al. Quantitative determination of the dopamine agonist lisuride in plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr 1993; 622: 33–8PubMedCrossRef
108.
Beattie IG, Blake TJ. Application of thermospray liquid chroma-tography-mass spectrometry and liquid chromatography-tandem mass spectrometry for the identification of cynomolgus monkey and human metabolites of SK & F 101468, a dopamine D2 receptor agonist. J Chromatogr 1989; 474: 123–38PubMedCrossRef
109.
Lau YY, Hanson GD, Ichhpurani N. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection. J Chromatogr B Biomed Appl 1996; 683: 217–23PubMedCrossRef
110.
Pianezzola E, Bellotti V, La Croix R, et al. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1992; 574: 170–4PubMedCrossRef
111.
Sarati S, Guiso G, Spinelli R, et al. Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1991; 563: 323–32PubMedCrossRef
112.
Friis ML, Paulson OB, Hertz MM. Transfer of bromocriptine across the blood-brain barrier in man. Acta Neurol Scand 1979; 59: 88–95PubMedCrossRef
113.
Lieberman AN, Goldstein M. Bromocriptine in Parkinson’s disease. Pharmacol Rev 1985; 37: 217–27PubMed
114.
Parkinson’s Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinsons disease: three year interim report. BMJ 1993; 307: 469–72CrossRef
115.
Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903–10PubMedCrossRef
116.
Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034–8PubMedCrossRef
117.
Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease. Neurology 1993; 43: 21–7PubMedCrossRef
118.
119.
Hely MA, Morris JG, Lawrence S, et al. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy. Aust N Z J Med 1991; 21: 82–4PubMedCrossRef
120.
Ayres J, Maisey MN. Alcohol increases bromocriptine’s side effects [letter]. N Engl J Med 1980; 302: 806PubMedCrossRef
121.
Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211–4PubMed
122.
Rubin A, Lemberger L, Dhahir P. Physiologic disposition of pergolide. Clin Pharmacol Ther 1981; 30: 258–65PubMedCrossRef
123.
Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573–9PubMedCrossRef
124.
Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, et al. A six-month study of pergolide and levodopa in de novo Parkinson’s disease patients. Clin Neuropharmacol 1998; 21: 358–62PubMed
125.
Wolters EC, Tissingh G, Bergmans PL, et al. Dopamine agonists in Parkinson’s disease. Neurology 1995; 45 Suppl. 3: S28–34PubMedCrossRef
126.
Rinne UK. Lisuride, a dopamine agonists in the treatment of early Parkinson’s disease. Neurology 1983; 39: 336–9CrossRef
127.
Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 1997; 49: 724–8PubMedCrossRef
128.
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91PubMedCrossRef
129.
Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23–30PubMedCrossRef
130.
Ziegler M, Lacomblez L, Rascol O, et al. Efficacy of piribedil in adjunction to L-dopa in a six-month randomized placebo controlled study in early Parkinson’s disease [abstract]. Neurology 2000; 45 Suppl. 3: A280
131.
Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49: 1060–5PubMedCrossRef
132.
Olanow CW, Fahn S, Muenter M, et al. A multicenter doubleblind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994; 9: 40–7PubMedCrossRef
133.
Lieberman AN, Goldstein M, Leibowitz M, et al. Lisuride combined with levodopa in advanced Parkinson disease. Neurology 1981; 31: 1466–9PubMedCrossRef
134.
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162–8PubMedCrossRef
135.
Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 1998; 51: 1057–62PubMedCrossRef
136.
Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 1996; 46: 1062–5PubMedCrossRef
137.
138.
Tanner CM, Goetz CG, Glantz RH, et al. Pergolide mesylate: four years experience in Parkinson’s disease. Adv Neurol 1987; 45: 547–9PubMed
139.
Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson’s disease. Adv Neurol 1983; 37: 95–108PubMed
140.
Le Witt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009–14CrossRef
141.
Goetz CG, Tanner CM, Glantz RH, et al. Chronic agonist therapy for Parkinson’s disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749–51PubMedCrossRef
142.
Goetz CG, Shannon KM, Tanner CM, et al. Agonist substitution in advanced Parkinson’s disease. Neurology 1989; 39: 1121–2PubMedCrossRef
143.
Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson’s disease. The Cochrane Database of Systematic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; Issue 2. Oxford: Update Software, 2000, CD000236
144.
Kurlan R, Miller C, Knapp R, et al. Double-blind assessment of potential pergolide-induced cardiotoxicity. Neurology 1986; 36: 993–5PubMedCrossRef
145.
Kando JC, Keck Jr PE, Wood PA. Pergolide-induced hypotension [letter]. DICP 1990; 24: 543PubMed
146.
Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991; 3: 151–201PubMedCrossRef
147.
Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1986; 1: 467–70PubMedCrossRef
148.
Nomoto M, Iwata S, Irifune M, et al. Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson’s disease. Nihon Shinkei Seishin Yakurigaku Zasshi 1998; 18: 81–7PubMed
149.
Humpel M, Nieuweboer B, Hasan SH, et al. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level. Eur J Clin Pharmacol 1981; 20: 47–51PubMedCrossRef
150.
Rinne UK. Combination therapy with lisuride and L-dopa in the early stages of Parkinson’s disease decreases and delays the development of motor fluctuations: long-term study over 10 years in comparison with L-dopa monotherapy. Nervenarzt 1999; 70 Suppl. 1: S19–25PubMedCrossRef
151.
Obeso JA, Luquin MR, Martinez Lage JM. Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 1986; 19: 31–5PubMedCrossRef
152.
Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson’s disease. Acta Neurol Scand 1992; 86: 593–5PubMedCrossRef
153.
Lieberman AN, Gopinathan G, Neophytides A, et al. Pergolide and lisuride in advanced Parkinson’s disease. Adv Neurol 1984; 40: 503–7PubMed
154.
Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson’s disease: response to chronic administration in 34 patients. Brain 1991; 114: 601–17PubMedCrossRef
155.
Capria A, Attanasio A, Quatrana M, et al. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson’s disease. Clin Neuropharmacol 1989; 12: 331–8PubMedCrossRef
156.
Lees AJ. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121–8PubMedCrossRef
157.
Cotzias GC, Lawrence WH, Papavasiliou PS, et al. Apomorphine and parkinsonism. Trans Amer Neurol Assoc 1972; 97: 156–9
158.
Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 1984; 107: 487–506PubMedCrossRef
159.
Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson’s disease [letter]. J Neurol Neurosurg Psychiatry 1990; 53: 1015PubMedCrossRef
160.
Lees AJ, Montastruc JL, Turjanski N, et al. Sublingual apomorphine and Parkinson’s disease [letter]. J Neurol Neurosurg Psychiatry 1989; 52: 1440PubMedCrossRef
161.
Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 96–101PubMedCrossRef
162.
Poewe W, Kleedorfer B, Gerstenbrand F, et al. Subcutaneous apomorphine in Parkinson’s disease [letter]. Lancet 1988; I: 943CrossRef
163.
Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165–70PubMedCrossRef
164.
Ellis CM, Lemmens G, Parkes JD. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Rel Disord 1997; 3: 103–7CrossRef
165.
Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 58: 681–7PubMedCrossRef
166.
Sampapio C, Branco MC, Rosa MM. A pharmacokinetic interaction between subcutaneous apomorphine and levodopa/carbidopa (Sinemet). Clin Drug Invest 1995; 9: 363–5CrossRef
167.
Coudore F, Durif F, Duroux E, et al. Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport 1997; 8: 877–80PubMedCrossRef
168.
Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol 1998; 21: 141–51PubMed
169.
Albani C, Popescu R, Lacher R, et al. Single dose response to pramipexole in patients with Parkinson’s disease [abstract]. Mov Disord 1992;7:P271
170.
Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease. Drugs Aging 1998; 12: 495–514PubMedCrossRef
171.
Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease: a randomized dose-ranging study. JAMA 1997; 278: 125–30CrossRef
172.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA 2000; 284: 1931–8CrossRef
173.
Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436–41PubMedCrossRef
174.
Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–10PubMedCrossRef
175.
Eden RJ, Costali B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK & F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991; 38: 147–54PubMedCrossRef
176.
Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 2000; 60: 115–137PubMedCrossRef
177.
Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997; 49: 393–9PubMedCrossRef
178.
Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group. Neurology 1999; 53: 364–70PubMedCrossRef
179.
Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline: rationale for use in Parkinson’s disease. Drugs 1998; 55 Suppl. 1: 10–6PubMedCrossRef
180.
Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs 1998; 55 Suppl. 1: 17–22PubMedCrossRef
181.
Del Dotto P, Colzi A, Musatti E, et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson’s disease. Clin Neuropharmacol 1997; 20: 455–65PubMedCrossRef
182.
Jenner P, Smith L, Jackson M, et al. Piribedil induces low levels of dyskinesia in MPTP-treated common marmosets [abstract]. Neurology 2000; 45 Suppl. 3: A53
183.
Jenner P, Taylor AR, Campbell DB. Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent. J Pharm Pharmacol 1973; 25: 749–50PubMedCrossRef
184.
Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease: use of the drug in the retard form. Clin Neuropharmacol 1989; 12: 23–8PubMedCrossRef
185.
Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239 Suppl. 1: S28–34PubMedCrossRef
186.
Dewey SL, Volkow ND, Logan J, et al. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res 1990; 27: 569–75PubMedCrossRef
187.
Krueger BK. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 1990; 55: 260–7PubMedCrossRef
188.
McDonough Jr JH Shih TM. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs. Pharmacol Biochem Behav 1995; 51: 249–53PubMedCrossRef
189.
Kornhuber J, Parsons CG, Hartmann S, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect 1995; 102: 237–46PubMedCrossRef
190.
He H, McKay G, Midha KK. Development of a sensitive and specific radioimmunoassay for benztropine. J Pharm Sci 1993; 82: 1027–32PubMedCrossRef
191.
Hollmann M, Brode E, Greger G, et al. Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 1984; 27: 619–21PubMedCrossRef
192.
Grimaldi R, Perucca E, Ruberto G, et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986; 29: 735–7PubMedCrossRef
193.
Rutigliano G, Labout JJ. The bioavailability of orphenadrine hydrochloride after intramuscular and oral administration. J Int Med Res 1982; 10: 447–50PubMed
194.
Whiteman PD, Fowle AS, Hamilton MJ, et al. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 1985; 28: 73–8PubMedCrossRef
195.
Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18: 35–40PubMedCrossRef
196.
He H, McKay G, Wirshing B, et al. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans. J Pharm Sci 1995; 84: 561–7PubMedCrossRef
197.
Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994; 46: 151–7PubMedCrossRef
198.
Myllylä VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson’s disease. Eur J Clin Pharmacol 1993; 45: 419–23PubMedCrossRef
199.
Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol 1996; 19: 283–96PubMedCrossRef
200.
Jorga K, Fotteler B, Banken L, et al. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 2000; 49: 39–48PubMedCrossRef
201.
Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50: 47–55PubMedCrossRef
202.
Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline: an update. Clin Pharmacokinet 1997; 33: 91–102PubMedCrossRef
203.
Owen JA, Sribney M, Lawson JS, et al. Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr 1989; 494: 135–42PubMedCrossRef
204.
Capka V, Xu Y, Chen YH. Stereoselective determination of trihexyphenidyl in human serum by LC-ESI-MS. J Pharm Biomed Anal 1999; 21: 507–17PubMedCrossRef
205.
Nation RL, Triggs EJ, Vine J. Metabolism and urinary excretion of benzhexol in humans. Xenobiotica 1978; 8: 165–9PubMedCrossRef
206.
Doshay LJ, Constable K. Five year follow-up of treatment with trihexyphenidyl (Artane®). JAMA 1954; 154: 1334–6CrossRef
207.
Takahashi S, Tohgi H, Yonezawa H, et al. The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. J Neurol Sci 1999; 167: 56–61PubMedCrossRef
208.
Guthrie SK, Manzey L, Scott D, et al. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers. J Clin Psychopharmacol 2000; 20: 77–83PubMedCrossRef
209.
Itoh K, Ikarashi Y, Way EL, et al. Intrastriatal dialysis evidence for a direct inhibitory effect of benztropine on dopamine reuptake. Neurosci Lett 1991; 125: 22–4PubMedCrossRef
210.
Selinger K, Lebel G, Hill HM, et al. High-performance liquid Chromatographic method for the analysis of benztropine in human plasma. J Chromatogr 1989; 491: 248–52PubMedCrossRef
211.
He H, McKay G, Midha KK. Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica 1995; 25: 857–72PubMedCrossRef
212.
Sureda FX, Gabriel C, Pallas M, et al. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology 1999; 38: 671–7PubMedCrossRef
213.
Contin M, Riva R, Albani F, et al. Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed Chromatogr 1987; 2: 193–4PubMedCrossRef
214.
Maurer H, Pfleger K. Screening procedure for the detection of alkanolamine antihistamines and their metabolites in urine using computerized gas chromatography-mass spectrometry. J Chromatogr 1988; 428: 43–60PubMedCrossRef
215.
Hattori H, Yamamoto S, Iwata M, et al. Determination of diphenylmethane antihistaminic drugs and their analogues in body fluids by gas chromatography with surface ionization detection. J Chromatogr 1992; 581: 213–8PubMedCrossRef
216.
Guo Z, Raeissi S, White RB, et al. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997; 25: 390–3PubMed
217.
Ellison T. Metabolic studies of 3H-orphenadrine citrate in the rat, dog and rhesus monkey. Arch Int Pharmacodyn Ther 1972; 195: 213–30PubMed
218.
Dean K, Land D, Bye A. Analysis of procyclidine in human plasma and urine by gas-liquid chromatography. J Chromatogr 1980; 221: 408–13PubMedCrossRef
219.
Holeman JA, Danielson ND. Microbore liquid chromatography of tertiary amine anticholinergic Pharmaceuticals with tris(2,2’-bipyridine)ruthenium(III) chemiluminescence detection. J Chromatogr Sci 1995; 33: 297–302PubMed
220.
Rogiers V, Paeme G, Sonck W, et al. Metabolism of procyclidine in isolated rat hepatocytes. Xenobiotica 1987; 17: 849–57PubMedCrossRef
221.
Le Bris T, Brode E. Capillary gas Chromatographic determination of biperiden in human plasma. Arzneimittelforschung 1985; 35: 149–51PubMed
222.
Stell L, Fleckenstein P, Riemann D, et al. A simple but highly sensitive radioreceptor assay for the determination of scopolamine and biperiden in human plasma. Res Commun Chem Pathol Pharmacol 1989; 64: 59–68
223.
Hollmann M, Muller-Peltzer H, Greger G, et al. Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers. Pharmacopsychiatry 1987; 20: 72–7PubMedCrossRef
224.
Sudo Y, Suhara T, Suzuki K, et al. Muscarinic receptor occupancy by biperiden in living human brain. Life Sci 1999; 64: 99–104CrossRef
225.
Villares JC, Carlini EA. Sebum secretion in idiopathic Parkinson’s disease: effect of anticholinergic and dopaminergic drugs. Acta Neurol Scand 1989; 80: 57–63PubMedCrossRef
226.
Schrag A, Schelosky L, Scholz U, et al. Reduction of Parkinsonian signs in patients with Parkinson’s disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 1999; 14: 252–5PubMedCrossRef
227.
Roberts J, Waller DG, von Renwick AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331–7PubMedCrossRef
228.
Contin M, Riva R, Martinelli P, et al. Combined levodopa-anticholinergic therapy in the treatment of Parkinson’s disease: effect on levodopa bioavailability. Clin Neuropharmacol 1991; 14: 148–55PubMedCrossRef
229.
Schwab RS, England AC, Poskanzer DC, et al. Amantadme in the treatment of Parkinson’s disease. JAMA 1969; 208: 1168–70PubMedCrossRef
230.
Kulisevsky J, Tolosa E. Amantadme in Parkinson’s disease. In: Koller WC, Paulson GW, editors. Therapy of Parkinson’s disease. New York: Marcel-Dekker, 1990: 143–60
231.
Stoof JC, Booij J, Drukarch B, et al. The anti-parkinsonian drug amantadme inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992; 213: 439–43PubMedCrossRef
232.
Deep P, Dagher A, Sadikot A, et al. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadme. Synapse 1999; 34: 313–8PubMedCrossRef
233.
Zhou FX, Krull IS, Feibush B. Direct determination of adamantanamine in plasma and urine with automated solid phase derivatization. J Chromatogr 1993; 619: 93–101PubMedCrossRef
234.
Shannon KM, Goetz CG, Carroll VS, et al. Amantadme and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 1987; 10: 522–6PubMedCrossRef
235.
Parkes JD, Baxter RC, Curzon G, et al. Treatment of Parkinson’s disease with amantadme and levodopa: a one-year study. Lancet 1971; I: 1083–6CrossRef
236.
Greulich W, Fenger E. Amantadme in Parkinson’s disease: pro and contra. J Neural Transm Suppl. 1995; 46: 415–21PubMed
237.
Dallos V, Heathfield K, Stone P, et al. The comparative value of amantadme and levodopa. Postgrad Med J 1972; 48: 354–8PubMedCrossRef
238.
Mawdsley C, Williams IR, Pullar IA, et al. Treatment of Parkinsonism with amantadme and levodopa. Clin Pharmacol Ther 1972; 13: 575–83PubMed
239.
Luginger E, Wenning GK, Bosch S, et al. Beneficiai effects of amantadme on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2000; 15: 873–8PubMedCrossRef
240.
Verhagen Metman L, Del Dotto P, LePoole K, et al. Amantadme for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383–6CrossRef
241.
Shulman LM, Minagar A, Sharma K, et al. Amantadine-induced peripheral neuropathy. Neurology 1999; 53: 1862–5PubMedCrossRef
242.
Nissinen E, Lindén IB, Schultz E, et al. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 262–6PubMedCrossRef
243.
Storch A, Blessing H, Bareiss M, et al. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons. Mol Pharmacol 2000; 57: 589–94PubMed
244.
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997; 42: 747–55CrossRef
245.
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51: 1309–14PubMedCrossRef
246.
Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the ’wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421–8PubMedCrossRef
247.
Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the ‘wearing-off’ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066–71PubMedCrossRef
248.
Karlsson M, Wikberg T. Liquid Chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992; 10: 593–600PubMedCrossRef
249.
Timm U, Erdin R. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 1992; 593: 63–8PubMedCrossRef
250.
Lehtonen P, Lehtinen S, Malkki-Laine L, et al. Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine. J Chromatogr A 1999; 836: 173–88PubMedCrossRef
251.
De Santi C, Giulianotti PC, Pietrabissa A, et al. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol 1998; 54: 215–9PubMedCrossRef
252.
Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s disease. Neurology 1994; 44: 1292–7PubMedCrossRef
253.
Wikberg T, Vuorela A, Ottoila P, et al. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993; 21: 81–92PubMed
254.
Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145–56PubMedCrossRef
255.
Nutt JG, Woodward WR, Beckner RM, et al. Effectof peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913–9PubMedCrossRef
256.
Piccini P, Brooks D, Korpela K, et al. Entacapone enhances the pharmacokinetic and clinical response of levodopa when administered with Sinemet depot [abstract]. Eur J Neurol 1998; 5 Suppl. 3: S 165
257.
Trocóniz IF, Naukkarinen TH, Ruottinen HM, et al. Population pharmacodynamic modeling of levodopa in patients with Parkinson’s disease receiving entacapone. Clin Pharmacol Ther 1998; 64: 106–16PubMedCrossRef
258.
Günther I, Psylla M, Reddy GN, et al. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. Nucl Med Biol 1995; 22: 921–7PubMedCrossRef
259.
Russ H, Muller T, Woitalla D, et al. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 719–20PubMedCrossRef
260.
Jorga KM, Kroodsma JM, Fotteler B, et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 1998; 63: 646–54PubMedCrossRef
261.
Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998; 245: 223–30PubMedCrossRef
262.
Tohgi H, Abe T, Yamazaki K, et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson’s disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192: 165–8PubMedCrossRef
263.
Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995; 40: 253–62PubMedCrossRef
264.
Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997; 49: 665–71PubMedCrossRef
265.
Adler CH, Singer C, O’Brien C, et al. Randomized, placebocontrolled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998; 55: 1089–95PubMedCrossRef
266.
Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81–7PubMedCrossRef
267.
Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov Disord 1997; 12: 928–34PubMedCrossRef
268.
Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999; 14: 38–44CrossRef
269.
Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease patients. Tolcapone De Novo Study Group. Mov Disord 1998; 13: 643–7PubMedCrossRef
270.
Assai F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis [letter]. Lancet 1998; 352: 958
271.
Ellison RH. Dear health professional letter regarding appropriate use of Tasmar. Nutley, (NJ): Roche Laboratories Inc, November 16, 1998
272.
273.
Olanow CW. Hepatic safety of the COMT inhibitor entacapone [abstract]. Neurology 2000; 54 Suppl. 3: A279
274.
Lyytinen J, Kaakkola S, Teräväinen H, et al. Comparison between the effects of L-dopa + entacapone and L-dopa + placebo on exercise capacity, haemodynamics and autonomic function in patients with Parkinson’s disease [abstract]. Mov Disord 1997; 12 Suppl. 1: 103CrossRef
275.
Sundberg S, Scheinin M, Ojala-Karlsson P, et al. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993; 36: 451–6PubMedCrossRef
276.
Deleu D. COMT inhibition in Parkinson’s disease: rationale and clinical relevance. Acta Neurol Belg 2000; 100: 5–7PubMed
277.
Deleu D. Endogenous dopamine-derived neurotoxins and Parkinson’s disease. Acta Neurol Belg 1998; 98: 319–21PubMed
278.
Jorga KM, Nicholl DJ. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). Br J Clin Pharmacol 1999; 48: 449–52PubMedCrossRef
279.
Jorga KM, Larsen JP, Beiske A, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999; 6: 211–9PubMedCrossRef
280.
Olanow CW, Mytilineou C, Tatton W. Current status of selegiline as a neuroprotective agent in Parkinson’s disease. Mov Disord 1998; 13 Suppl. 1: 55–8PubMed
281.
Dingemanse J, Wood N, Jorga K, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br J Clin Pharmacol 1997; 43: 41–7PubMedCrossRef
282.
Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30: 666–72PubMedCrossRef
283.
La Croix R, Pianezzola E, Strolin Benedetti M. Sensitive high-performance liquid Chromatographic method for the determination of the three main metabolites of selegiline (L-deprenyl) in human plasma. J Chromatogr B Biomed Appl 1994; 656: 251–8PubMedCrossRef
284.
Salonen JS. Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography. J Chromatogr 1990; 527: 163–8PubMedCrossRef
285.
Reimer ML, Mamer OA, Zavitsanos AP, et al. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas Chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 1993; 22: 235–42PubMedCrossRef
286.
Laine K, Anttila M, Huupponen R, et al. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 2000; 23: 22–7PubMedCrossRef
287.
Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (selegiline) withdrawal. Synapse 1994; 18: 86–93PubMedCrossRef
288.
The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 32: 1364–71
289.
Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson’s disease. Ann Neurol 1995; 37: 95–8PubMedCrossRef
290.
Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602–7PubMedCrossRef
291.
Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995; 38: 771–7PubMedCrossRef
292.
The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993; 328: 176–83CrossRef
293.
Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520–5PubMedCrossRef
294.
Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29–36CrossRef
295.
Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39: 37–45CrossRef
296.
Ward CD. Does selegiline delay the progression of Parkinson’s disease: a critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994; 57: 217–20PubMedCrossRef
297.
Rinne JO. Nigral degeneration in Parkinson’s disease in relation to clinical features. Acta Neurol Scand Suppl. 1991; 316: 87–90CrossRef
298.
Olanow CW, Myllylä VV, Sotaniemi KA, et al. Effect of selegiline on mortality in patients with Parkinson’s disease: a metaanalysis. Neurology 1998; 51: 825–30PubMedCrossRef
299.
Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson’s disease: a longitudinal community study. Neurology 2000; 55: 1785–9PubMedCrossRef
300.
Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s disease. Drugs Aging 1991; 1: 228–48PubMedCrossRef
301.
Pal S, Bhattacharya KF, Agapito C, et al. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson’s disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001; 108: 71–7PubMedCrossRef
302.
Ferreira JJ, Galitzky M, Montastruc JL, et al. Sleep attacks and Parkinson’s disease treatment. Lancet 2000; 355: 1333–4PubMedCrossRef
303.
Etminan M, Samii A, Takkouche B, et al. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863–8PubMedCrossRef
Metadata
Title
Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease
Authors
Dr Dirk Deleu
Margaret G. Northway
Yolande Hanssens
Publication date
01-04-2002
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2002
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200241040-00003